Ripples maintain time-locked occurrence across the septo-temporal axis and hemispheres while showing local phase coupling, revealing a dual mode of synchrony in CA1 network dynamics.

The change in policy comes after Sir Keir Starmer wrote to President Emmanuel Macron urging him to back the plan, according to reports in France. In a change of stance from French authorities, ...

France is backing away from a recent commitment to intervene more forcefully at sea to stop small boats from crossing the English Channel, according to multiple sources contacted by the BBC. There is ...

Videos shared with the BBC shows a police boat circling a small boat in a shallow canal near the sea in Gravelines France is backing away from a recent commitment to intervene more forcefully at sea ...

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

The North American Aerospace Defense Command (NORAD) scrambled fighter jets on Wednesday to identify and intercept four Russian military planes off Alaska, the U.S and Canadian defense organization ...

Three Russian MiG-31 Foxhound fighters violated Estonian airspace, prompting the scramble of two Italian F-35s to intercept them. Three MiG-31 Foxhound fighters of the Russian Aerospace Forces entered ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...